

Discovery of a 'First-In-Class' New Drug for IPF Treatment



RESPIRATORY	Candidate
Product Type	Small Molecule
Indication	Idiopathic Pulmonary Fibrosis (IPF)
Target	ARPC2: Actin related protein complex 2
MoA(Mechanism of Action)	Inhibition of transition of alveolar fibroblast to pathogenic myofibroblast
Competitiveness	First-in-class, a novel antifibrotic agent that could be used as monotherapy or as an add-on to current IPF therapies
Development Stage	Candidate
Route of Administration	Oral